Company intelligence / Profile preview
Hormosan Pharma
Frankfurt am Main, Hessen, Germanyhormosan.com ↗
- Ownership
- Private
- Employees
- ~94
- Development stage
- Other
01
Overview
Hormosan Pharma markets 61 products in Germany—54 of which are generics. The company does not develop its own new chemical entities but acquires finished developments or existing approvals for commercialization. Its focus areas include CNS/pain indications and sexual health. Recent growth has been driven by neurology sector products and new launches.
- Therapeutic areas
- NeurologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Not specifically disclosed; parent company Lupin has global partnerships.
Beyond the preview
Go deeper on Hormosan Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hormosan Pharma.